Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City. Carlo Russo, Chief Medical Officier, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET). To register for one-on-one meetings with management... Read More

MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell... Read More

MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million)... Read More

MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private... Read More

Over 230 Italian and U.S. executives, Italian government leaders, and investors attended the eighth edition of "Italy On the Move" Seven life sciences executives provided business insights during "Navigating Transatlantic Partnerships in Life Sciences" panel discussion and five Italian startups pitched their unique breakthroughs and investment opportunities Director General for the Promotion of Italy Mauro Battocchi... Read More

MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master Services Agreement. This amendment introduces an exclusive GMP suite at the... Read More

Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector 1 SAN FRANCISCO , Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign... Read More

MILAN and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” scheduled at 2.00 PM on October 25 th , 2024 at the U.S. Senate - Washington,... Read More

MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta’s flagship product, Temferon™. This approval by... Read More

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the... Read More

MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: We have successfully dosed the first of three patients in Cohort 8 (Temferon™ at 4x10^6/kg), the last cohort of the Phase 1... Read More

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences. H.C. Wainwright 25th Annual Global Investment Conference , September 11-13 2023,... Read More

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: the Phase 1... Read More

MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the European Commission has granted Orphan Drug Designation (ODD) to Temferon ™ for the treatment of glioma . Glioblastoma Multiforme... Read More

MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini , Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage immuno-oncology company, will be presenting the company cell-based platform harnessing the power of hematopoietic stem cells to provide durable, safe, and well tolerated treatment for solid tumors at several upcoming scientific... Read More

Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025 Net exchange rate gain of €2.3 million Tax credit of €6.4 million MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe... Read More

MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor... Read More

MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma... Read More

MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers... Read More